

## VEGFR3/FLT4 Protein, Human, Recombinant (hFc)

### General Information

Synonyms:	FLT41;fms related tyrosine kinase 4;VEGF Receptor 3;PCL;FLT-41;VEGFR-3;LMPH1A;FLT-4;VEGFR3
Protein Construction:	Tyr25-Ile776
Species:	Human
Expression Host:	HEK293 Cells
Accession:	P35916-1
Molecular Weight:	111.3 kDa (Predicted); 135-155 kDa (Due to glycosylation)

### QC Testing

Biological Activity:	Immobilized Human VEGF-C, His Tag at 1 µg/ml (100 µl/well) on the plate. Dose response curve for Human VEGF R3, hFc Tag with the EC50 of 17.9 ng/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Lyophilized from 0.22µm filtered solution in 50mM Tris, 150mM NaCl, 100mM Glycine (pH 7.5). Normally 8% trehalose is added as protectant before lyophilization.

### Preparation and Storage

#### Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 µg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

#### Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

#### Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

### Protein Background

Vascular endothelial growth factor (VEGF) and its receptors VEGF-R1, -R2 and -R3 play important roles in tumor angiogenesis and are associated with poor prognosis in several solid tumors. VEGF-R1, -R2 and -R3 were highly expressed in CRC cells and stromal vessels. VEGF-R1 strong positive staining correlated with shorter survival after CRC surgery.

### Reference

- Shushanov S, et al. (2000) VEGF<sub>C</sub> and VEGFR<sub>3</sub> expression in human thyroid pathologies. *Int J Cancer*. 86(1): 47-52.
- Iljin K, et al. (2001) VEGFR<sub>3</sub> gene structure, regulatory region, and sequence polymorphisms. *FASEB J*. 15(6): 1028-36.
- Liu XE, et al. (2004) Expression and significance of VEGF-C and FLT-4 in gastric cancer. *World J Gastroenterol*. 10(3): 352-5.
- Stearns ME, et al. (2004) Expression of a flt-4 (VEGFR<sub>3</sub>) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. *Lab Invest*. 84(6): 785-95.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286    E\_mail: info@targetmol.com    Address: 34 Washington Street, Wellesley Hills, MA 02481